A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors

被引:339
|
作者
Crabtree, JS
Scacheri, PC
Ward, JM
Garrett-Beal, L
Emmert-Buck, MR
Edgemon, KA
Lorang, D
Libutti, SK
Chandrasekharappa, SC
Marx, SJ
Spiegel, AM
Collins, FS
机构
[1] NHGRI, NIH, Bethesda, MD 20892 USA
[2] NCI, NIH, Bethesda, MD 20892 USA
[3] NIDDKD, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1073/pnas.98.3.1118
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer syndrome, characterized primarily by multiple tumors in the parathyroid glands, endocrine pancreas, and anterior pituitary. Other tumors, including gastrinoma, carcinoid, adrenal cortical tumors, angiofibroma, collagenoma, and lipoma, also occur in some patients. Individuals with MEN1 almost always have loss-of-function mutations in the MEN1? gene on chromosome 11, and endocrine tumors arising in these patients usually show somatic loss of the remaining wild-type allele. To examine the role of MEN1 in tumor formation, a mouse model was generated th rough homologous recombination of the mouse homolog Men 1. Homozygous mice die in utero at embryonic days 11.5-12.5, whereas heterozygous mice develop features remarkably similar to those of the human disorder. As early as 9 months, pancreatic islets show a range of lesions from hyperplasia to insulin-producing islet cell tumors, and parathyroid adenomas are also frequently observed. Larger, more numerous tumors involving pancreatic islets, parathyroids, thyroid, adrenal cortex, and pituitary are seen by 16 months. All of the tumors tested to date show loss of the wild-type Men1 allele, further supporting its role as a tumor suppressor gene.
引用
收藏
页码:1118 / 1123
页数:6
相关论文
共 50 条
  • [41] Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1
    Yliaska, Iina
    Tokola, Heikki
    Ebeling, Tapani
    Kuismin, Outi
    Ukkola, Olavi
    Koivikko, Minna L.
    Lesonen, Timo
    Rimpilainen, Jussi
    Felin, Tuuli
    Ryhanen, Eeva
    Metso, Saara
    Schalin-Jantti, Camilla
    Salmela, Pasi
    ENDOCRINE, 2022, 77 (03) : 527 - 537
  • [42] Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies
    Agarwal, Sunita K.
    INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2014, 1 (02) : 153 - 161
  • [43] Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1
    Busygina, V
    Suphapeetiporn, K
    Marek, LR
    Stowers, RS
    Xu, TA
    Bale, AE
    HUMAN MOLECULAR GENETICS, 2004, 13 (20) : 2399 - 2408
  • [44] Multiple endocrine neoplasia type 1 with pyonephrosis
    Satoh, A
    Iigaya, T
    INTERNATIONAL JOURNAL OF UROLOGY, 2002, 9 (07) : 402 - 404
  • [45] MULTIPLE ENDOCRINE NEOPLASIA TYPE-1
    YAMAGUCHI, K
    KAMEYA, T
    ABE, K
    CLINICS IN ENDOCRINOLOGY AND METABOLISM, 1980, 9 (02): : 261 - 284
  • [46] Surgical Management of Multiple Endocrine Neoplasia 1 and Multiple Endocrine Neoplasia 2
    Kiernan, Colleen M.
    Grubbs, Elizabeth G.
    SURGICAL CLINICS OF NORTH AMERICA, 2019, 99 (04) : 693 - +
  • [47] Multiple endocrine neoplasia type 1 associated with multiple lipomas
    Hofmann, M
    Schilling, T
    Heilmann, P
    Haisken, O
    Wuster, C
    Brandi, ML
    Ziegler, R
    Nawroth, PP
    MEDIZINISCHE KLINIK, 1998, 93 (09) : 546 - 549
  • [48] FAMILIAL MULTIPLE ENDOCRINE ADENOMATOSIS - MULTIPLE ENDOCRINE NEOPLASIA, TYPE I
    CRAVEN, DE
    CARTER, JH
    GOODMAN, AD
    ARCHIVES OF INTERNAL MEDICINE, 1972, 129 (04) : 567 - +
  • [49] Multiple endocrine neoplasia type 1 (MEN 1)
    不详
    MEDICINA DELLO SPORT, 2007, 60 (03) : 407 - 411
  • [50] Pancreatic endocrine tumors with loss of heterozygosity at the multiple endocrine neoplasia type I locus
    Eubanks, PJ
    Sawicki, MP
    Samara, GJ
    Wan, YJY
    Gatti, RA
    Hurwitz, M
    Passaro, E
    AMERICAN JOURNAL OF SURGERY, 1997, 173 (06): : 518 - 520